Table 1 The demographic, clinical and pathological characteristics of the study population
Characteristics | Poor survival group | Extended survival group | p value |
|---|---|---|---|
(n = 63)* | (n = 49)* | ||
Age | 0.196 | ||
< 40 | 5 (7.9) | 3 (6.1) | |
40 - 49 | 18 (28.6) | 14 (28.6) | |
50 - 59 | 21 (33.3) | 11 (22.4) | |
60 - 69 | 16 (25.4) | 12 (24.5) | |
≥ 70 | 3 (4.8) | 9 (18.4) | |
Gravidity | 0.576 | ||
0 - 1 | 7 (11.1) | 5 (10.2) | |
2 - 3 | 29 (46.0) | 19 (38.8) | |
4 - 5 | 16 (25.4) | 11 (22.4) | |
≥ 5 | 11 (17.5) | 14 (28.6) | |
Parity | 0.551 | ||
0 - 1 | 42 (66.7) | 30 (61.2) | |
2 - 3 | 21 (33.3) | 19 (38.8) | |
Menopause | 0.789 | ||
Yes | 37 (58.7) | 30 (61.2) | |
No | 26 (41.3) | 19 (38.8) | |
Ascites | 0.382 | ||
Yes | 10 (15.9) | 5 (10.2) | |
No | 53 (84.1) | 44 (89.8) | |
Peritoneal metastasis** | <0.001# | ||
Yes | 25 (39.7) | 5 (10.2) | |
No | 38 (60.3) | 44 (89.8) | |
Lymphatic metastasis | 0.024# | ||
Yes | 19 (30.2) | 6 (12.2) | |
No | 44 (69.8) | 43 (87.8) | |
Stage | <0.001# | ||
I | 6 (9.5) | 21 (42.9) | |
II | 21 (33.3) | 20 (40.8) | |
III | 26 (41.3) | 7 (14.3) | |
IV | 10 (15.9) | 1 (2.0) | |
Histotype | 0.420 | ||
Serous | 38 (60.3) | 26 (53.1) | |
Mucinous | 5 (7.9) | 9 (18.4) | |
Endometrioid | 9 (14.3) | 8 (16.3) | |
Clear cell | 7 (11.1) | 5 (10.2) | |
Undifferentiated | 4 (6.3) | 1 (2.0) | |
Grade | 0.076 | ||
G1 | 9 (14.3) | 15 (30.6) | |
G2 | 28 (44.4) | 21 (42.9) | |
G3 | 26 (41.3) | 13 (26.5) | |
Size of residual site | 0.007# | ||
< 2 cm | 43 (68.3) | 44 (89.8) | |
≥ 2 cm | 20 (31.7) | 5 (10.2) |